Impact Factor
1.92
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.65
72 total citations
h5-index
10
h5 depth signal
Cited share
21.6%
27 of 125
Total citations
72
Citation footprint
Metric signal
0.22
External metric anchor
Self-citation
0.0%
0 self-citations
Citations Trend
Citing Geographic Demographics
China
626
United States
5
Citing Fields of Research
Hepatitis
95
Liver Diseases
73
Liver & Colon Cancer
33
Pharmacology & Toxicology
7
Immunology
7
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,113
Articles tracked across the journal lifetime
Indexed publication set
125
27 cited publications
Last 12 months
0
0.0 publications/month
Open access share
0.0%
0 OA publications in the last year
Leading citing country
China
626 citing publications
Leading citing field
Hepatitis
95 citing publications
Latest tracked publication
20 December 2023
10 recent records available
Coverage & Indexing History
v7n1,1999-
v7n1,1999-
Active Coverage
Active Coverage
Research Focus & Classification
Issuing & Sponsoring Bodies
Contributor
Chongqing yi ke da xue. Bing du xing gan yan yan jiu suo
Broad Categories
Gastroenterology
MeSH Descriptors
Liver Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.3760/cma.j.cn501113-20230214-00056
Open DOI
[Significance of triggering receptor expressed on myeloid cells-2 prognostic evaluation in hepatitis B virus-related acute-on-chronic liver failure].
Objective: To explore the significance of triggering receptor expressed on myeloid cells-2 (TREM-2) prognostic evaluation so as to provide novel biological markers in clinical practice for patients with hepatitis B virus-related acute-on...
02
DOI 10.3760/cma.j.cn501113-20230914-00105
Open DOI
[Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma].
Objective: To analyze the correlation between the histological classification of hepatocellular carcinoma (HCC), especially macrotrabecular-massive (MTM), tumor invasiveness, and prognosis. Methods: The clinical and follow-up data of 246...
03
DOI 10.3760/cma.j.cn501113-20220216-00068
Open DOI
[Analysis of severe liver injury in a patient treated with oxaliplatin, capecitabine, and a PD-1 inhibitor: a case report].
免疫相关性肝炎临床诊断主要依据其用药史、肝脏生化指标、激素治疗应答等来综合诊断。现报道1例奥沙利铂、卡培他滨联合程序性死亡受体1（PD-1）抑制剂治疗直肠癌期间出现重度肝损伤，依据其临床特点、治疗反应等，结果显示PD-1导致此次肝损伤可能性大，给...
04
DOI 10.3760/cma.j.cn501113-20230915-00108
Open DOI
[Emphasis on targeted and immunotherapy for liver injury in hepatocellular carcinoma].
Treatment with molecular targeted drugs and immune checkpoint inhibitors (ICIs) has become the first-line treatment options for unresectable HCC (hepatocellular carcinoma) and is also one of the anti-recurrence therapies of choice for pa...
05
DOI 10.3760/cma.j.cn501113-20230928-00129
Open DOI
[Strategies for immunotherapy-related hepatotoxicity in liver cancer].
The successful market availability of immune checkpoint inhibitors (ICIs) has brought revolutionary changes to the treatment of hepatocellular carcinoma (HCC). With the widespread application of ICIs in HCC patients, the impact or even t...
06
DOI 10.3760/cma.j.cn501113-20230905-00090
Open DOI
[Strategies for liver injury caused by hepatocellular carcinoma targeted therapy].
Primary hepatocellular carcinoma has a high degree of malignancy, insidious onset, and rapid progression that seriously threatens human life and health. With the continuous deepening of the study of the molecular characteristics of tumor...
07
DOI 10.3760/cma.j.cn501113-20230914-00107
Open DOI
[Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].
The occurrence rate of primary liver cancer in malignant tumors ranks sixth in the world, and the mortality rate ranks third, with a poor prognosis and a five-year survival rate of less than 5%. Most patients with liver cancer in China a...
08
DOI 10.3760/cma.j.cn501113-20230925-00120
Open DOI
[Chinese expert consensus on the clinical management of liver disease-associated thrombocytopenia syndrome].
Liver disease-associated thrombocytopenia syndrome refers to thrombocytopenia caused by liver disease or the treatment of liver disease, and its incidence rate is related to the duration and severity of liver disease. The direct effect o...
09
DOI 10.3760/cma.j.cn501113-20230915-00109
Open DOI
[A clinical study of targeted immunotherapy combined with hepatic arterial chemoembolization in the treatment of liver injury associated with primary liver cancer].
Objective: To investigate the conditions of occurrence and factors influencing liver injury caused by molecular targeted drugs and immune checkpoint inhibitors combined with hepatic arterial chemoembolization (TACE) in the treatment of p...
10
DOI 10.3760/cma.j.cn501113-20230827-00070
Open DOI
[Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and advanced-stage liver cancer].
Objective: To compare the postoperative liver function injury condition in patients with intermediate-and advanced-stage hepatocellular carcinoma (HCC) treated with hepatic artery infusion chemotherapy (HAIC) and hepatic artery chemoembo...
Bibliographical & Catalog Notes
Description based on: di 4 juan, di 1 qi (1996 nian 5 yue); title from cover.
Vols. for <1996>- also called: <Vol. 4, no. 1 (May, 1996)>-
Also issued online.
In Chinese; abstracts and table of contents also in English.
Vol. 7, no. 1 (1999)19990316 Notice published Printed on acid-free paper